Test Definition: THSD7
THSD7A Ab, S

Overview

Useful For
Distinguishing primary from secondary membranous nephropathy

Method Name
Indirect Immunofluorescence Assay (IFA)

NY State Available
Yes

Specimen

Specimen Type
Serum

Specimen Required

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container: Plastic vial

Specimen Volume: 1 mL

Collection Information: Centrifuge within 2 hours. Aliquot and ship in plastic vial.

Forms
If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.

Specimen Minimum Volume
0.5 mL

Reject Due To

<table>
<thead>
<tr>
<th>Gross hemolysis</th>
<th>Reject</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gross lipemia</td>
<td>OK</td>
</tr>
</tbody>
</table>

Specimen Stability Information

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Temperature</th>
<th>Time</th>
<th>Special Container</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum</td>
<td>Refrigerated (preferred)</td>
<td>14 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Frozen</td>
<td>14 days</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ambient</td>
<td>8 hours</td>
<td></td>
</tr>
</tbody>
</table>
Clinical and Interpretive

Clinical Information

Recently, autoantibodies against phospholipase A2 receptor (PLA2R) in the kidney were determined to be the major target antigen for patients with idiopathic/primary membranous nephropathy (MN). (1) Approximately 70% of patients with primary MN circulate anti-PLA2R antibodies, and in the remaining 30% (who are PLA2R-negative), antithrombospondin type-1 domain-containing 7A (THSD7A) was shown to have approximately a 10% prevalence (or about 3% of all primary MN patients). (2) Mouse podocytes express THSD7A and introduction of anti-THSD7A autoantibodies induces MN in murine models. Mouse podocytes do not express PLA2R so exogenous administration of anti-PLA2R does not recapitulate membranous nephropathy in mice. (3) Additionally, THSD7A has been described as a potential tumor antigen and, thus, it has been suggested that THSD7A-positive patients merit a thorough cancer screening. (4)

Reference Values

Negative

Interpretation

Therapy outcome can be monitored by measuring the antibody titer. A titer increase, decrease, or disappearance generally precedes a change in clinical status. Thus, the determination of the antibody titer has a high predictive value with respect to clinical remission, relapse, or risk assessment after kidney transplantation.

Cautions

This test should not be used as a stand-alone test but as an adjunct to other clinical information. A diagnosis of primary or secondary membranous nephropathy (MN) should not be made based on a single test result. The clinical symptoms, results on physical examination, and laboratory tests (eg, serological tests), when appropriate, should always be taken into account when considering the diagnosis of primary versus secondary MN.

Absence of circulating autoantibodies does not rule out a diagnosis of primary MN.

Clinical Reference


Performance

Method Description

Diluted patient samples are incubated with combinations of substrates. If the reaction is positive, specific antibodies of classes IgA, IgG, and IgM attach to the antigens. In a second step, the attached antibodies are stained with fluorescein-labelled antihuman antibodies and made visible with a fluorescence microscope. (Package insert: EUROIMMUN Anti-THSD7A IFA Kit, EUROIMMUN US, Morris Plains, NJ, V 9/19/2016)
PDF Report
No

Day(s) and Time(s) Test Performed
Tuesday; Batched

Analytic Time
3 days

Maximum Laboratory Time
7 days

Specimen Retention Time
7 days

Performing Laboratory Location
Rochester

Fees and Codes

Fees
- Authorized users can sign in to Test Prices for detailed fee information.
- Clients without access to Test Prices can contact Customer Service 24 hours a day, seven days a week.
- Prospective clients should contact their Regional Manager. For assistance, contact Customer Service.

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information
86255

LOINC® Information

<table>
<thead>
<tr>
<th>Test ID</th>
<th>Test Order Name</th>
<th>Order LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>THSD7</td>
<td>THSD7A Ab, S</td>
<td>93339-0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Result ID</th>
<th>Test Result Name</th>
<th>Result LOINC Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>THSD7</td>
<td>THSD7A Ab, S</td>
<td>93339-0</td>
</tr>
</tbody>
</table>